Shots:
- P-Ib/IIa (iLSTA) trial assessed certepetide (LSTA1; iRGD cyclic peptide) ± SoC CT ± Imfinzi in LA inoperable PDAC pts (N=30) randomized into 3 arms, with A1 (n=5) receiving SoC CT + PBO Imfinzi & PBO certepetide; A2 (n=5) receiving SoC CT + certepetide & PBO Imfinzi; A3 (n=20) receiving SoC CT + Imfinzi & certepetide
- Initial data (from 16 RECIST evaluable pts) was presented at ASCO GI 2025, showed 5 PRs (4 from A3) after 2 cycles of therapy & 11 SDs
- After 4 cycles, the study depicted 9 PRs (8 from A3), 1 CR (A2) & 6 SDs, >90% CA19-9 level reduction in 6 pts (5 from A3) & >50% CA19-9 level reduction in 8 pts (6 from A3). 5 pts had a significant immune cell infiltration (4 from A3)
Ref: Lisata Therapeutics | Image: Lisata Therapeutics & WARPNINE
Related News:- Lisata Therapeutics Collaborates with Kuva Labs to Advance Non-Invasive, High-Precision Cancer Diagnostics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
